Amprenavir Side Effects
Some side effects of amprenavir may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to amprenavir: oral capsule liquid filled, oral solution
Along with its needed effects, amprenavir may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor as soon as possible if any of the following side effects occur while taking amprenavir:More common
- Burning or prickling sensation in arms or legs
- dry or itchy skin
- increased cholesterol and triglycerides
- increased hunger
- increased thirst
- increased urination
- skin rash
- mood or mental changes
- Back, leg or stomach pains
- bleeding gums
- blistering, peeling, or loosening of skin and mucous membranes
- buffalo hump
- dark urine
- difficult breathing
- general body swelling
- general feeling of discomfort or illness
- loss of appetite
- pale skin
- sore throat
- unexplained weight loss
- yellowing of eyes or skin
Some side effects of amprenavir may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common
- Abdominal pain
- burning or prickling sensation around the mouth
- Change in sense of taste
- unusual tiredness or weakness
For Healthcare Professionals
Applies to amprenavir: oral capsule, oral solution
Gastrointestinal side effects and skin rashes were the most frequent side effects in clinical trials of amprenavir in combination with other antiretrovirals. Gastrointestinal effects (nausea, vomiting, diarrhea, and abdominal pain) most often resulted in discontinuation of amprenavir during the first 12 weeks of treatment. Skin rashes had a median onset and duration of 11 and 10 days, respectively, and led to discontinuation of amprenavir in 3% of patients.
Gastrointestinal side effects have included nausea (74%), vomiting (34%), and diarrhea or loose stools (39%) in clinical trials when amprenavir was administered with lamivudine and zidovudine in therapy-naive patients. This compares to an incidence of 50%, 17%, and 34%, respectively, when therapy-naive patients were only administered lamivudine and zidovudine. Abdominal symptoms (unspecified, 14%) and anorexia have been reported in patients receiving amprenavir in combination with ritonavir plus other antiretrovirals.
Rashes were usually maculopapular, mild to moderate in intensity, and some with pruritus. The onset of rash development was approximately 10 days and ranged from 7 to 73 days. Amprenavir was often continued with mild to moderate rash and if discontinued, rash did not recur when the drug was restarted. Amprenavir should be discontinued for severe or life-threatening rashes and for moderate rashes accompanied by systemic symptoms.
Dermatologic side effects have been reported frequently. Skin rash occurred in 28% of HIV-1 infected patients treated with amprenavir in all multidose studies. Severe or life-threatening rash, including Stevens-Johnson syndrome, occurred in 1% of patients.
Metabolic side effects have included hyperglycemia (37%), hypertriglyceridemia (36%), and hypercholesterolemia (4%) in clinical trials when amprenavir was administered with lamivudine and zidovudine in therapy-naive nonfasting patients. This compares to an incidence of 29%, 22% and 3%, respectively, when therapy-naive nonfasting patients were only administered lamivudine and zidovudine. Grade 3/4 hypertriglyceridemia (8% to 13%) and hyperglycemia (2% to 3%) have been reported in patients receiving amprenavir in combination with ritonavir. New onset and exacerbation of preexisting diabetes mellitus, elevated serum creatine kinase, and ketoacidosis have also been reported.
Hepatic side effects have included elevations in AST (greater than 5 times ULN), ALT (greater than 5 times ULN), and amylase (greater than 2 times ULN) in 3% to 5% of patients receiving amprenavir in combination with ritonavir.
Nervous system side effects have included oral/perioral paresthesia (26%) and other paresthesias (10%), including peripheral paresthesias, in clinical trials when amprenavir was administered with lamivudine and zidovudine in therapy-naive patients. This compares to an incidence of 6% and 4%, respectively, when therapy-naive patients were only administered lamivudine and zidovudine. Headache (12% to 16%) has been reported in patients receiving amprenavir in combination with ritonavir plus other antiretrovirals.
Psychiatric side effects have included depression and mood disorder in 15% of therapy-naive patients who were administered amprenavir with lamivudine and zidovudine in clinical trials. This compares to an incidence of 4% when therapy-naive patients were only administered lamivudine and zidovudine.
Hematologic side effects have included neutropenia and hemolytic anemia. Hematologic side effects associated with protease inhibitors have included spontaneous bleeding in patients with hemophilia A and B. In many of the reported cases, treatment with protease inhibitors was continued or restarted and some patients required additional factor VIII. A causal relationship between protease inhibitor therapy and these episodes has not been established.
Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement, peripheral wasting, breast enlargement, and "cushingoid appearance" have been observed in patients receiving protease inhibitors. The mechanism and long-term consequences of these events are currently unknown and a causal relationship has not been established. In one case, reduction of neck fat disposition (buffalo hump) was reported when amprenavir replaced indinavir in a regimen.
Other side effects have included taste disorders in 10% of therapy-naive patients who were administered amprenavir with lamivudine and zidovudine in clinical trials. This compares to an incidence of 5% when therapy-naive patients were only administered lamivudine and zidovudine. Fatigue (7% to 14%) and chills have been reported in patients receiving amprenavir in combination with ritonavir plus other antiretrovirals.
Hypersensitivity side effects have included urticaria.
More amprenavir resources
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.